^
Association details:
| Biomarker: | MET overexpression |
|---|---|
| Cancer: | Pancreatic Cancer |
| Drug: | TR1801-ADC (DNA replication inhibitor, c-MET-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A MET Targeting Antibody-Drug Conjugate Overcomes Gemcitabine Resistance in Pancreatic Cancer
Published date:
01/15/2021
Excerpt:
We show that MET is highly expressed and located at the plasma membrane of pancreatic cancer cells. We found that TR1801-ADC induces a specific cytotoxicity in pancreatic cancer cell lines and a profound tumor growth inhibition, even in a gemcitabine resistant tumor. We also noted synergism between TR1801-ADC and gemcitabine in vitro and an improved response to the combination in vivo.
Secondary therapy:
gemcitabine
DOI:
10.1158/1078-0432.CCR-20-3210
